New bowel cancer test shows greater than 90% accuracy in high-risk patients
A new method for detecting bowel cancer is more than 90% accurate at predicting which higher risk people will develop the disease, research has shown.
People with inflammatory bowel disease (IBD), such as Crohn's and ulcerative colitis, are known to have an increased chance of bowel cancer, but not all will develop it.
Now, a study, funded by Cancer Research UK, has shown more than 90% accuracy in predicting bowel cancer risk in the next five years in a high-risk group of people with IBD.
This could lead to a blood test which will inform doctors which IBD patients are most at risk of bowel cancer.
We can accurately identify those people at high risk whilst putting the minds of many others at rest
Professor Trevor Graham, ICR
Professor Trevor Graham, from the Institute of Cancer Research (ICR), which co-led the research, said: 'Most people with ulcerative colitis or Crohn's disease won't develop bowel cancer.
'But for those that have these conditions and are showing signs of pre-cancer in their colon, there are some tough decisions to make.
'Either they have it monitored regularly, in the hope that it doesn't become cancer, or they have their bowel removed to guarantee they don't get cancer in the future. Neither of these options are particularly pleasant.
'Our test and algorithm give people with IBD, and the doctors who care for them, the best possible information so that they can make the right decision about how to manage their cancer risk.
'We can accurately identify those people at high risk whilst putting the minds of many others at rest.'
Patients with inflammatory bowel disease have a higher risk of developing colorectal cancer than people without IBD, and need to undergo assessment with regular colonoscopies to try to detect early signs of cancer
Professor Ailsa Hart
IBD can irritate the lining of the bowel and can cause abnormal pre-cancerous cells to form if left untreated.
To identify people's cancer risk, scientists at the ICR, working with doctors at St Mark's, the UK's specialist bowel hospital, found that people with IBD whose pre-cancerous cells had lost multiple copies of their DNA were far more likely to go on to develop bowel cancer.
The scientists also created an algorithm that calculates the risk of future bowel cancer, based on the exact pattern of the DNA which is altered in the pre-cancerous cells.
Taken together, scientists hope the findings could spare people who are at much lower risk from the stress of needing regular colonoscopies or undergoing surgery to remove the colon.
Professor Ailsa Hart, co-lead of the study, from St Mark's, said: ' Patients with inflammatory bowel disease have a higher risk of developing colorectal cancer than people without IBD, and need to undergo assessment with regular colonoscopies to try to detect early signs of cancer.
Getting a full readout of tumour DNA means we can see a much bigger picture of how someone's cancer started and how it is likely to change over time
Dr Iain Foulkes, Cancer Research UK
'These tests are onerous and unpleasant for patients, imperfect at detecting early cancer changes and costly to health services.
'If early signs of cancer are detected, surgery, which involves removing the colon, is advocated. Finding smarter ways to assess these colons is much needed.
'Here we describe a potential biomarker, which can be readily translated into clinical practice, to improve assessment of patients with IBD and early signs of cancer to help with the decision for surgery.'
Executive director of research and innovation at Cancer Research UK, Dr Iain Foulkes, said: 'Genome sequencing is now far cheaper and more widespread than ever before, and it's changing how we look at cancer.
'Getting a full readout of tumour DNA means we can see a much bigger picture of how someone's cancer started and how it is likely to change over time.
'With this research, we can focus resources on treating people with IBD who are at really high risk, saving health services valuable time and money.
'We can also give those at lower risk peace of mind and remove the fear of bowel cancer in the future.'
In the study, published in the journal Gut, samples of pre-cancerous cells were taken from 122 patients with IBD.
About half of the patients went on to develop bowel cancer within five years, whilst the other half remained cancer-free.
All of the samples had their full DNA scanned to look for changes in the structure and number of copies in the DNA.
The scientists found that patients with IBD who developed bowel cancer had lost multiple copies of their DNA.
About 500,000 people in the UK are thought to have Crohn's or ulcerative colitis.
Marianne Radcliffe, chief executive of Crohn's and Colitis UK, said the test was 'hugely exciting', adding: 'This is really positive news for people with Crohn's and Colitis; just as with inflammatory bowel disease, we know the earlier you find out about cancer, the better.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
12 minutes ago
- BBC News
Southampton pancreatic cancer blood test trial seeks patients
A programme to evaluate a blood test for early signs of pancreatic cancer has started to recruit Safe-D study, based in Southampton, Hampshire, is signing up patients with type 2 diabetes, which is a known risk factor for the blood test is reported to be 68% accurate in detecting pancreatic cancer markers, according to initial disease often has vague symptoms and can lead to death within months of diagnosis. Sean Cleghorn's wife, Allison, discovered she had pancreatic cancer at Christmas in 2020 and died four weeks later at the age of father of three, from Kingsclere, Hampshire, said: "The only symptom Allison displayed was some slight indigestion and then she was diagnosed with type 2 diabetes in the autumn of 2020."Allison had always eaten healthily, was active and avoided processed food, so this diagnosis was puzzling for us. Mr Cleghorn added: "When we learned that new-onset type 2 diabetes was a potential risk factor for pancreatic cancer, we asked for further testing and a scan confirmed she had terminal cancer."Perhaps if she had been diagnosed sooner with a test like the one that's currently being trialled, we may have had time to make more memories with our three children."The Avantect blood test will be evaluated at the Cancer Research UK Southampton Clinical Trials recruits will have blood samples tested to help design the main surgeon Zaed Hamady who is leading the study said: "Although most people with diabetes will not go on to develop the disease, new onset diabetes is associated with a six- to eight-fold increased risk."This patient group gives us a way to test how accurate the new diagnostic blood test is."Previously, researchers have claimed successes for pancreatic cancer tests involving urine samples and nematode no test is reliable and accurate enough for a national screening programme, according to the charity Pancreatic Cancer UK. You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
The Sun
2 hours ago
- The Sun
Blood test to detect early signs of deadliest cancer trialled in UK – and doctors are calling for people to take part
A NEW blood test to pick up early signs of a cancer which kills more than half of people within three months of diagnosis is being trialled by UK doctors. The genomic test uses blood samples to look for markers of the deadly disease, which often has vague symptoms. 2 Currently, the UK doesn't have a national screening programme for pancreatic cancer like it does for breast or bowel cancer. A huge issue is the disease is often diagnosed at a late stage because it frequently lacks noticeable symptoms in the early stages. But a new pancreatic cancer test is being trialled in patients with a recent diagnosis of type 2 diabetes - a known risk factor for the disease. People over 50 with a new case of type 2 diabetes have a higher chance of also being diagnosed with pancreatic cancer within three years. Early data suggests the Avantect test is 68 per cent accurate in picking up people with early stages of the disease, which kills almost 10,000 people every year in the UK. It's also 97 per cent accurate in ruling out people without pancreatic cancer. The new clinical trial has been launched at the Cancer Research UK Southampton Clinical Trials Unit. Zaed Hamady, consultant surgeon and pancreatic researcher at the University of Southampton, who's leading the trial, said: "There is currently no targeted early detection or surveillance test for the disease meaning patients are often diagnosed late when they become really unwell. "If we can develop approaches to detect the cancer sooner, then there are more options we may consider to treat the disease, and patients will have a much better chance of long-term survival. "Although most people with diabetes will not go on to develop the disease, new onset diabetes is associated with a six to eight-fold increased risk. "This patient group gives us a way to test how accurate the new diagnostic blood test is, and that could potentially help thousands of people in the future." According to researchers, newly-diagnosed type 2 diabetes patients often have similar symptoms as a person with early-stage pancreatic cancer. This is because the cancer destroys the same insulin-producing cells that are also destroyed in diabetes. 'Earlier diagnosis would have meant time to make more memories with our children' Sean Cleghorn's wife, Allison, discovered she had pancreatic cancer at Christmas 2020 but died four weeks later aged 54. Mr Cleghorn, a father of three from Kingsclere in Hampshire, said: "The only symptom Allison displayed was some slight indigestion and then she was diagnosed with type 2 diabetes in the autumn of 2020. "Allison had always eaten healthily, was active and avoided processed food, so this diagnosis was puzzling for us. "When we learned that new-onset type 2 diabetes was a potential risk factor for pancreatic cancer, we asked for further testing and a scan confirmed she had terminal cancer. "We hoped she could have chemotherapy to prolong her life, but she became too weak and died four weeks later. "Perhaps if she had been diagnosed sooner with a test like the one that's currently being trialled, we may have had time to make more memories with our three children." Angelica Cazaly, senior trial manager for the trial, said: "We are asking people with newly diagnosed type 2 diabetes who are attending GP surgeries or diabetic clinics whether they would like to take part in the study. "Initially, we will collect blood samples from 800 people for testing. "The results from the test, together with medical information collected from each patient, will help provide researchers with important information on how best to proceed with the rest of the study that will evaluate how accurate the test is at predicting pancreatic cancer." 'Exciting time for early detection research' 2 Around 10,500 people in the UK are diagnosed with pancreatic cancer every year and just one in 20 survive the disease for 10 years or more. Samuel Levy, chief scientific officer of ClearNote Health, said: "Our early data demonstrate that our Avantect test can identify pancreatic cancer in stages I and II. "We are excited to collaborate with the Cancer Research UK Southampton Clinical Trials Unit and the University Hospital Southampton NHS Foundation Trust on this transformative study that could redefine how pancreatic cancer is detected and managed for patients at high risk." Dr Chris Macdonald, head of research at Pancreatic Cancer UK, said over 80 per cent of people with pancreatic cancer are currently diagnosed too late for treatment. He added: "This is an exciting time for early detection research, with tests using blood, breath and urine in development which, if shown to be successful in clinical trials, could save thousands of lives every year. "Early findings from these tests are very promising, but more research is needed to ensure that they are as accurate as possible before they will be available in the GP surgery."
The Independent
12 hours ago
- The Independent
Northern Ireland scientists lead study aimed at helping identify cancer earlier
A new study aims to find a way to identify patients with early signs of cancer through medications they are prescribed. It is hoped the project, led by researchers in Belfast and funded by Cancer Research UK, could help identify various cancers at an early stage when treatment is more likely to be effective. A team of researchers including Professor Chris Cardwell, Professor Carmel Hughes, Dr Sarah Baxter, Dr David Wright and Dr Blanaid Hicks from Queen's University Belfast, with Professor Peter Murchie from the University of Aberdeen, will study extensive anonymised medical information to identify treatments given to people who are then diagnosed with cancer. The researchers say it will be the first of its kind to study prescription information comprehensively in the UK. Similar studies have been carried out overseas and smaller studies conducted looking at fewer cancer types in the UK. Previous studies have already shown increased use of pain and indigestion medication in women with ovarian cancer up to eight months before diagnosis and increases in haemorrhoid treatments in patients with colorectal cancer up to 15 months before diagnosis. Prof Cardwell said: 'Our study has the potential to identify previously unrecognised medications which are newly used in the period up to two years before cancer diagnosis. 'These changes in specific medications could act as an alert for doctors to consider earlier cancer investigation or point to unrecognised symptom patterns. 'Diagnosing cancer as early as possible is key to ensuring treatment is as effective as possible and give patients the best chance of recovery.' The study, which will receive £76,462 from Cancer Research UK, will focus on eight cancers – multiple myeloma, pancreatic, stomach, ovarian, lung, renal, colorectal and non-Hodgkin's lymphoma – selected because these cancers are known to involve more GP consultations prior to diagnosis. Currently, there are many symptoms and medical conditions known to be associated with cancer, but often symptoms can indicate a variety of conditions, not just cancer, making diagnosis harder. Prescription data from the Secure Anonymised Information Linkage Databank at Swansea University, which works with the NHS to provide information for researchers while keeping data anonymous and protected, will be used. This requires permission from the databank's Information Governance Review Panel which oversees the safe and responsible use of population health records. The researchers said codes used in the NHS to indicate medication prescriptions are easier to analyse and track than symptoms. An increase in dose or stronger medication can be flagged more easily to medical colleagues than notes on a patient's record saying a symptom is worsening. Cancer Research UK director of research Dr Catherine Elliott said: 'Innovative approaches to tackling cancer are crucial to improving outcomes for patients. 'We have already made great strides in turning many types of cancer into a treatable disease if diagnosed at an early stage, and studies like this aim to help doctors identify people at risk of cancer much earlier. 'Earlier diagnosis takes us further along the path towards a world where cancer diagnosis is the start of the road to recovery and a less fearful prospect for patients.'
